Logo image of NVAX

NOVAVAX INC (NVAX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NVAX - US6700024010 - Common Stock

6.53 USD
-0.01 (-0.15%)
Last: 12/17/2025, 7:31:00 PM
6.55 USD
+0.02 (+0.31%)
After Hours: 12/17/2025, 7:31:00 PM
Fundamental Rating

4

Overall NVAX gets a fundamental rating of 4 out of 10. We evaluated NVAX against 529 industry peers in the Biotechnology industry. NVAX has a medium profitability rating, but doesn't score so well on its financial health evaluation. NVAX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year NVAX was profitable.
In the past year NVAX has reported a negative cash flow from operations.
In the past 5 years NVAX always reported negative net income.
In the past 5 years NVAX reported 4 times negative operating cash flow.
NVAX Yearly Net Income VS EBIT VS OCF VS FCFNVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

NVAX's Return On Assets of 28.96% is amongst the best of the industry. NVAX outperforms 97.92% of its industry peers.
NVAX's Return On Invested Capital of 43.90% is amongst the best of the industry. NVAX outperforms 99.43% of its industry peers.
Industry RankSector Rank
ROA 28.96%
ROE N/A
ROIC 43.9%
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVAX Yearly ROA, ROE, ROICNVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

NVAX's Profit Margin of 32.10% is amongst the best of the industry. NVAX outperforms 96.22% of its industry peers.
NVAX has a better Operating Margin (39.15%) than 98.30% of its industry peers.
With an excellent Gross Margin value of 91.82%, NVAX belongs to the best of the industry, outperforming 92.82% of the companies in the same industry.
Industry RankSector Rank
OM 39.15%
PM (TTM) 32.1%
GM 91.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVAX Yearly Profit, Operating, Gross MarginsNVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NVAX is creating value.
The number of shares outstanding for NVAX has been increased compared to 1 year ago.
The number of shares outstanding for NVAX has been increased compared to 5 years ago.
NVAX has a worse debt/assets ratio than last year.
NVAX Yearly Shares OutstandingNVAX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
NVAX Yearly Total Debt VS Total AssetsNVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

NVAX has an Altman-Z score of -2.34. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.34, NVAX perfoms like the industry average, outperforming 47.45% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.34
ROIC/WACC5.05
WACC8.7%
NVAX Yearly LT Debt VS Equity VS FCFNVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

NVAX has a Current Ratio of 2.27. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NVAX (2.27) is worse than 74.29% of its industry peers.
A Quick Ratio of 2.24 indicates that NVAX has no problem at all paying its short term obligations.
The Quick ratio of NVAX (2.24) is worse than 72.78% of its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 2.24
NVAX Yearly Current Assets VS Current LiabilitesNVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

5

3. Growth

3.1 Past

NVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 165.04%, which is quite impressive.
The Revenue has grown by 20.27% in the past year. This is a very strong growth!
Measured over the past years, NVAX shows a very strong growth in Revenue. The Revenue has been growing by 105.31% on average per year.
EPS 1Y (TTM)165.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.47%
Revenue 1Y (TTM)20.27%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-16.64%

3.2 Future

Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.51% on average per year.
The Revenue is expected to decrease by -13.97% on average over the next years. This is quite bad
EPS Next Y239.44%
EPS Next 2Y31.07%
EPS Next 3Y23.09%
EPS Next 5Y17.51%
Revenue Next Year55.16%
Revenue Next 2Y-27.91%
Revenue Next 3Y-28.13%
Revenue Next 5Y-13.97%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NVAX Yearly Revenue VS EstimatesNVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
NVAX Yearly EPS VS EstimatesNVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15 -20

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 4.44, which indicates a rather cheap valuation of NVAX.
Compared to the rest of the industry, the Price/Earnings ratio of NVAX indicates a rather cheap valuation: NVAX is cheaper than 99.62% of the companies listed in the same industry.
NVAX is valuated cheaply when we compare the Price/Earnings ratio to 26.22, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for NVAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 4.44
Fwd PE N/A
NVAX Price Earnings VS Forward Price EarningsNVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

NVAX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NVAX is cheaper than 99.62% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.12
NVAX Per share dataNVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NVAX's earnings are expected to grow with 23.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y31.07%
EPS Next 3Y23.09%

More info and screens

0

5. Dividend

5.1 Amount

NVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

NOVAVAX INC

NASDAQ:NVAX (12/17/2025, 7:31:00 PM)

After market: 6.55 +0.02 (+0.31%)

6.53

-0.01 (-0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners60.94%
Inst Owner Change1.54%
Ins Owners0.41%
Ins Owner Change0.98%
Market Cap1.06B
Revenue(TTM)1.06B
Net Income(TTM)341.74M
Analysts73.33
Price Target12.92 (97.86%)
Short Float %34.98%
Short Ratio12.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)412.33%
Min EPS beat(2)-3.3%
Max EPS beat(2)827.96%
EPS beat(4)2
Avg EPS beat(4)268.3%
Min EPS beat(4)-58.31%
Max EPS beat(4)827.96%
EPS beat(8)4
Avg EPS beat(8)103.35%
EPS beat(12)7
Avg EPS beat(12)71.73%
EPS beat(16)7
Avg EPS beat(16)-6.56%
Revenue beat(2)2
Avg Revenue beat(2)61.22%
Min Revenue beat(2)58.52%
Max Revenue beat(2)63.92%
Revenue beat(4)4
Avg Revenue beat(4)53.78%
Min Revenue beat(4)2.61%
Max Revenue beat(4)90.08%
Revenue beat(8)5
Avg Revenue beat(8)24.49%
Revenue beat(12)7
Avg Revenue beat(12)22.3%
Revenue beat(16)8
Avg Revenue beat(16)9.73%
PT rev (1m)-9.52%
PT rev (3m)-4.66%
EPS NQ rev (1m)-34%
EPS NQ rev (3m)28.33%
EPS NY rev (1m)-1.11%
EPS NY rev (3m)-0.11%
Revenue NQ rev (1m)-16.12%
Revenue NQ rev (3m)-21.31%
Revenue NY rev (1m)-0.37%
Revenue NY rev (3m)-1.19%
Valuation
Industry RankSector Rank
PE 4.44
Fwd PE N/A
P/S 1
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.12
EPS(TTM)1.47
EY22.51%
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-2.36
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS6.55
BVpS-0.96
TBVpS-1.66
PEG (NY)0.02
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 28.96%
ROE N/A
ROCE 55.58%
ROIC 43.9%
ROICexc N/A
ROICexgc N/A
OM 39.15%
PM (TTM) 32.1%
GM 91.82%
FCFM N/A
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.54
Cap/Depr 15.47%
Cap/Sales 0.51%
Interest Coverage 19.68
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 2.24
Altman-Z -2.34
F-Score6
WACC8.7%
ROIC/WACC5.05
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)165.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.47%
EPS Next Y239.44%
EPS Next 2Y31.07%
EPS Next 3Y23.09%
EPS Next 5Y17.51%
Revenue 1Y (TTM)20.27%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-16.64%
Revenue Next Year55.16%
Revenue Next 2Y-27.91%
Revenue Next 3Y-28.13%
Revenue Next 5Y-13.97%
EBIT growth 1Y243.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year278.83%
EBIT Next 3Y14.17%
EBIT Next 5YN/A
FCF growth 1Y46.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.24%
OCF growth 3YN/A
OCF growth 5YN/A

NOVAVAX INC / NVAX FAQ

Can you provide the ChartMill fundamental rating for NOVAVAX INC?

ChartMill assigns a fundamental rating of 4 / 10 to NVAX.


Can you provide the valuation status for NOVAVAX INC?

ChartMill assigns a valuation rating of 5 / 10 to NOVAVAX INC (NVAX). This can be considered as Fairly Valued.


How profitable is NOVAVAX INC (NVAX) stock?

NOVAVAX INC (NVAX) has a profitability rating of 4 / 10.


How financially healthy is NOVAVAX INC?

The financial health rating of NOVAVAX INC (NVAX) is 3 / 10.